Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Developmental Biology Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NFIB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NFIB Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for biophysical binding assays. |
View NFIB Products |
| Gene Delivery | NFIB Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and phenotypic validation. |
View NFIB Products |
| Benchmark Ab | Anti-NFIB Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View NFIB Products |
| Validator | NFIB siRNA Set For target knockdown verification and specificity profiling. |
View NFIB Products |
| Related Target A | NFIA Homologous transcription factor; critical for selectivity and counter-screening panels. |
View NFIA Products |
| Related Target B | NFIX NFI family member; required to rule out off-target effects in pan-NFI programs. |
View NFIX Products |
| Related Target C | MYC Synergistic oncogenic driver; co-amplified or co-regulated with NFIB in aggressive malignancies. |
View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| NFI Family Selectivity (NFIA/NFIX/NFIC) | High-purity recombinant NFIA, NFIB, and NFIX proteins strictly verified by mass spectrometry. |
| Intracellular Target Access & Validation | Lentiviral vectors for stable overexpression to study chromatin accessibility and downstream gene regulation. |
| Lack of Controls | Sequence-validated recombinant antibodies and siRNA sets included for robust assay baselines. |
| False Positives in Small Molecule Screen | Sequence-verified, endotoxin-controlled proteins to ensure reliable biophysical binding signals (SPR/FP). |
Live NFIB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NFIB therapeutics is intensifying, with major players shifting focus from traditional transcription factor undruggability to novel modalities such as Targeted Protein Degradation (PROTACs/Molecular Glues) and RNA-targeted therapeutics. As first-generation epigenetic and transcriptional regulators reach the clinic, the next wave of R&D is targeting NFIB directly to combat metastasis and treatment-induced lineage plasticity.
NFIB (Nuclear Factor I B) is widely recognized as a master regulator of small cell lung cancer (SCLC) progression, triple-negative breast cancer (TNBC) metastasis, and neural stem cell differentiation. Because transcription factors lack classical small-molecule binding pockets, current therapeutic strategies focus heavily on disrupting its interaction with chromatin remodeling complexes or accelerating its degradation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Targeted Protein Degradation (PROTAC) | Arvinas, C4 Therapeutics, Academic Labs | Small Cell Lung Cancer (SCLC), Metastatic TNBC | Ternary Complex Assay (Need high-purity, sequence-verified recombinant NFIB protein) |
| RNA Interference (siRNA/ASO) | Alnylam, Ionis Pharmaceuticals | Advanced Solid Tumors, Glioblastoma | In Vitro Knockdown Validation (Need sequence-specific NFIB siRNA & Lentivirus) |
| Small Molecule Inhibitors (DBD Blockers) | Academic Consortia, Emerging Biotechs | Melanoma, Pediatric Brain Tumors | DNA-Binding Inhibition Assay (Need native-conformation NFIB proteins and NFI family counter-screening) |